Chelsea Therapeutics reports positive Phase III results Print E-mail
By Staff and Wire Reports   
Monday, 20 September 2010 12:09
Chelsea Therapeutics ranked as the lead gainer in the drug sector today, its shares rallied as the biotech company reported positive Phase III data for Northera, a prospective treatment for a chronic type of low blood pressure. The shares rocketed nearly 40% to $6.96 in early trading.

Our readers have been in on the secret that is Chelsea Therapeutics since mid-August. The company said that the drug met the main goal of improving the symptoms related to low blood pressure compared to a dummy drug. Northera also showed a statistically significant improvement in standing systolic blood pressure compared to the dummy drug.

Last September, the drug had failed in a late-stage trial as it could not show statistically significant improvement over a dummy drug.

"We are extremely excited by these top-line results which provide validation of the safety and efficacy of Northera as a novel treatment for symptomatic neurogenic orthostatic hypotension, a serious condition for which there is an urgent need for improved treatments," said Dr. Simon Pedder, president and CEO of Chelsea Therapeutics. "Symptoms of chronic neurogenic orthostatic hypotension are severe, not only putting patients at high risk for falls and associated injuries but also severely impacting their quality of life and generating significant added health care costs. Northera is the first and only drug to repeatedly demonstrate clinical improvement in these patients by both alleviating symptoms of neurogenic orthostatic hypotension and improving their ability to perform daily activities."




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter